Chronos
exploratoryplatform · medium · Thu Mar 12 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Reconstruct disease trajectories before clinical manifestation by linking archived plasma samples with longitudinal clinical records and modeling molecular changes over time.
Privacy-preserving tokenization of archived plasma samples and clinical records, followed by longitudinal proteomic profiling across more than 25,000 proteoforms.
2026 medRxiv report applied Chronos to Parkinson's disease using 2,609 plasma samples from 348 cases and 348 matched controls, with replication in up to five independent cohorts.
The framework reproduced proteomic signatures from clinically phenotyped cohorts and predicted future Parkinson's diagnosis with maximum cross-validated AUC of 0.76.
ECM Plasma Proteomic Aging Clock
exploratorybiomarker · medium · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Estimate biological aging and distinguish healthy versus diseased states using circulating extracellular matrix proteins.
A 14-protein plasma extracellular matrix aging clock constructed from public proteomic datasets and validated across independent datasets and biofluids.
2026 Aging Cell publication reporting cross-species ECM clocks and reversal of ECM aging signatures by rejuvenation interventions.
The ECM clock predicted chronological age, distinguished healthy and diseased states, and prioritized ECM proteins implicated causally in disease with potential drug targets.
GRF6021
undiscloseddrug program · high · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate whether a plasma-derived product can affect postoperative recovery, inflammatory response, immune signaling, and cognition-related outcomes in older or neurologically impaired populations.
Intravenous infusion of GRF6021 or young donor plasma protein fraction in clinical studies, with proteomic and immune-cell analyses in the surgical recovery study.
Published randomized clinical trial in 2025 reporting effects of young donor plasma components on immune and inflammatory response to surgical tissue injury; underlying ClinicalTrials.gov study NCT03981419 was published 2019-07-12.
In older joint-replacement patients, young plasma protein fraction altered proteomic and cellular immune responses to surgical trauma, including anti-inflammatory modulation of JAK-STAT, NF-kappa B, and MAPK-related pathways.
AKST4290
undiscloseddrug program · high · Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate AKST4290/ALK4290 for inflammatory, retinal, and neurodegenerative disease indications including diabetic retinopathy, bullous pemphigoid, neovascular or wet age-related macular degeneration, and Parkinson's disease.
Oral AKST4290/ALK4290 administered in placebo-controlled or adjunctive clinical studies, including combination with aflibercept for newly diagnosed nAMD.
CAPRI clinical trial to evaluate oral AKST4290 in participants with moderately severe to severe diabetic retinopathy, published 2021-08-17.
AKST1210
undiscloseddrug program · high · Thu Mar 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate AKST1210 in end-stage renal disease patients on hemodialysis, including patients with cognitive impairment.
AKST1210 column used during hemodialysis, including safety and tolerability assessment at blood-flow rates up to 450 mL/min.
Clinical study comparing safety and tolerability of AKST1210 column at two blood-flow rates in ESRD subjects on hemodialysis, published 2021-03-11.
GRF6019
undiscloseddrug program · high · Tue Jan 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate safety, tolerability, feasibility, and potential cognitive benefit of GRF6019 in Alzheimer's disease.
Intravenous infusion of GRF6019, described as a plasma-derived product, in subjects with mild-to-moderate or severe Alzheimer's disease.
Clinical study assessing safety of GRF6019 infusions in subjects with severe Alzheimer's disease, published 2019-01-15.
Novel Factors
exploratoryresearch program · medium
Identify plasma factors and plasma-proteome changes that may influence human biology and provide therapeutic or biomarker opportunities for age-related disease.
Artificial intelligence, integrative multiomics analysis, real-world data, and plasma protein expertise applied to plasma proteome data.
Listed in Alkahest's pipeline alongside AKST4290, AKST/GRF6019/6021, and AKST1210.
